📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Sanofi Consumer Healthcare Q4 Profit Jumps 50% to ₹665 MN; ₹75 Dividend Declared
Sanofi Consumer Healthcare India (SCHIL) reported a robust Q4 performance with revenue growing 47% YoY to ₹2,510 million and net profit surging 50% to ₹665 million. For the full year 2025, the company achieved a 21% revenue growth and a 33% increase in PAT, reaching ₹2,401 million. The board has recommended a substantial dividend of ₹75 per share, reflecting strong cash generation. Growth was primarily driven by a 23% rise in domestic sales and the successful relaunch of recalled products.
Key Highlights
Q4 Revenue grew 47% YoY to ₹2,510 million, while Net Profit rose 50% to ₹665 million.
Full-year FY25 PAT increased by 33% to ₹2,401 million on total revenue of ₹8,784 million.
Declared a significant dividend of ₹75 per share for the financial year ended December 31, 2025.
Domestic sales grew by 23% in Q4, supported by brand relaunches and core portfolio strength.
Export sales for Q4 grew 9.3x and full-year exports grew 158%, albeit from a low base.
💼 Action for Investors
The strong double-digit growth and high dividend payout indicate successful post-demerger stabilization and operational efficiency. Investors may consider this a positive signal for long-term value in the consumer healthcare space, given the strength of brands like Combiflam and Allegra.
Sanofi Consumer Healthcare FY25 Net Profit Jumps 33% to ₹240 Cr; Recommends ₹75 Dividend
Sanofi Consumer Healthcare India reported a strong financial performance for the year ended December 31, 2025, with annual revenue growing 21% to ₹8,784 million. Net profit for the full year surged by 32.6% to ₹2,401 million, driven by robust operational performance and higher other income. The Board has recommended a substantial final dividend of ₹75 per equity share, highlighting strong cash flow generation. Quarterly growth was even more pronounced, with Q4 revenue increasing 47% year-on-year to ₹2,510 million.
Key Highlights
Full-year FY25 revenue increased 21.2% to ₹8,784 million from ₹7,245 million in FY24.
Net profit for FY25 rose to ₹2,401 million, up from ₹1,810 million in the previous year.
Board recommended a final dividend of ₹75 per equity share (750% of face value).
Earnings Per Share (EPS) for FY25 improved significantly to ₹104.27 from ₹78.59.
Q4 FY25 net profit stood at ₹665 million, a 50% increase compared to ₹443 million in Q4 FY24.
💼 Action for Investors
Investors should view these results positively given the strong double-digit growth in both top-line and bottom-line, coupled with a high dividend payout. The stock remains attractive for those seeking a combination of growth in the consumer healthcare space and high yield.
Sanofi Consumer Healthcare Recommends Rs 75 Dividend; FY25 Net Profit Rises 33%
Sanofi Consumer Healthcare India has recommended a final dividend of Rs. 75 per share for the financial year ended December 31, 2025. The company reported a strong financial performance with annual revenue growing 21% to Rs. 8,784 million. Net profit for the full year increased significantly by 33% to Rs. 2,401 million compared to the previous year. The quarterly performance was also robust, with Q4 profit rising to Rs. 665 million from Rs. 443 million year-on-year.
Key Highlights
Recommended a final dividend of Rs. 75 per equity share of face value Rs. 10.
Annual Revenue from Operations grew 21.2% YoY to Rs. 8,784 million in FY25.
Net Profit for the full year surged 32.7% to Rs. 2,401 million from Rs. 1,810 million.
Earnings Per Share (EPS) increased to Rs. 104.27 from Rs. 78.59 in the previous year.
Q4 FY25 revenue stood at Rs. 2,510 million, a 47% increase over Q4 FY24.
💼 Action for Investors
Investors should note the strong growth trajectory and the substantial dividend payout which reflects robust cash flows. The stock is likely to be viewed favorably by both growth and income-seeking investors due to the earnings outperformance.
Sanofi Consumer Healthcare FY25 Net Profit Jumps 33% to ₹2,401 Mn; ₹75/Share Dividend Declared
Sanofi Consumer Healthcare India reported a strong performance for the financial year ended December 31, 2025, with annual revenue growing 21% to ₹8,784 million. Net profit for the full year increased significantly by 32.6% to ₹2,401 million, supported by improved operational efficiencies. The Board has recommended a substantial final dividend of ₹75 per share, reflecting a high payout ratio and strong cash position. Quarterly performance was also robust, with Q4 revenue up 47% year-on-year to ₹2,510 million.
Key Highlights
Full-year FY25 Revenue from Operations rose 21.2% YoY to ₹8,784 million versus ₹7,245 million.
Net Profit for FY25 increased to ₹2,401 million from ₹1,810 million in the previous year.
Recommended a final dividend of ₹75 per equity share of face value ₹10 for the financial year.
Q4 FY25 Net Profit grew 50% YoY to ₹665 million compared to ₹443 million in Q4 FY24.
Earnings Per Share (EPS) improved significantly to ₹104.27 for FY25 from ₹78.59 in FY24.
💼 Action for Investors
Investors should react positively to the strong double-digit growth in both revenue and profitability alongside a very generous dividend payout. The company's transition and focus on consumer healthcare appear to be yielding high margins and robust cash flows.